



## TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26599000 Fax: + 91 79 26582100  
CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores except per share data)				
Statement of Standalone Audited Financial Results for the Quarter ended June 30, 2024				
Particulars	Quarter ended			Year ended
	30-Jun-2024	31-Mar-2024 (Refer note 3)	30-Jun-2023	31-Mar-2024
<b>1 Revenue from operations</b>				
Net sales	2394	2094	2078	8370
Other operating income	44	49	43	163
<b>Total revenue from operations</b>	<b>2438</b>	<b>2143</b>	<b>2121</b>	<b>8533</b>
<b>2 Other income (Refer note 5)</b>	<b>21</b>	<b>76</b>	<b>11</b>	<b>91</b>
<b>3 Total income (1 + 2)</b>	<b>2459</b>	<b>2219</b>	<b>2132</b>	<b>8624</b>
<b>4 Expenses</b>				
Cost of materials consumed	410	409	434	1652
Purchases of stock-in-trade	141	168	113	548
Changes in inventories of finished goods, work-in-progress and stock-in-trade	32	(39)	(40)	(69)
Employee benefits expense	406	353	369	1451
Finance costs	64	67	90	303
Depreciation and amortisation expense	189	195	183	761
Other expenses	550	536	508	2061
<b>Total expenses</b>	<b>1792</b>	<b>1689</b>	<b>1657</b>	<b>6707</b>
<b>5 Profit before tax (3 - 4)</b>	<b>667</b>	<b>530</b>	<b>475</b>	<b>1917</b>
<b>6 Tax expense</b>				
Current tax	117	82	82	322
Deferred tax	81	38	70	238
<b>Total tax expense</b>	<b>198</b>	<b>120</b>	<b>152</b>	<b>560</b>
<b>7 Net profit for the period (5 - 6)</b>	<b>469</b>	<b>410</b>	<b>323</b>	<b>1357</b>
<b>8 Other comprehensive income</b>				
(A) (i) Items that will not be reclassified subsequently to profit or loss	(5)	6	(8)	(10)
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	2	(3)	3	3
(B) (i) Items that will be reclassified subsequently to profit or loss	5	16	59	58
(ii) Income tax relating to items that will be reclassified subsequently to profit or loss	(2)	(5)	(21)	(20)
<b>Total other comprehensive income*</b>	<b>0</b>	<b>14</b>	<b>33</b>	<b>31</b>
<b>9 Total comprehensive income (7 + 8)</b>	<b>469</b>	<b>424</b>	<b>356</b>	<b>1388</b>
<b>10 Paid-up equity share capital (Face value of Rs. 5 each)</b>	<b>169.23</b>	<b>169.23</b>	<b>169.23</b>	<b>169.23</b>
<b>11 Other equity excluding revaluation reserves</b>				<b>6660</b>
<b>12 Earnings per share (Face value of Rs. 5 each) (not annualised for the quarter) :</b>				
Basic	13.86	12.12	9.55	40.10
Diluted	13.86	12.12	9.55	40.10

\*Less than Rs. 1 crore

See accompanying notes to the standalone financial results



**Notes:**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on July 23, 2024. The statutory auditors have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- 2 The Company operates in a single segment i.e Generic Formulation Business.
- 3 Figures for the quarter ended March 31, 2024 represents the difference between the audited figures in respect to the full financial year and the published figures of nine months ended December 31, 2023 which were subjected to audit.
- 4 The listed non-convertible debentures of the company aggregating Rs. 285 crores as at June 30, 2024 (previous year ended Rs. 285 crores) are secured by way of first *pari-passu* charge through mortgage on certain specified immovable & tangible movable assets and hypothecation of identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount and interest accrued of the said debentures.
- 5 Other income mainly includes interest income, dividend income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets.
- 6 Refer Annexure I for disclosure required pursuant to Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

For TORRENT PHARMACEUTICALS LIMITED



A handwritten signature in black ink, appearing to read "SAMIR MEHTA".

**SAMIR MEHTA**  
Executive Chairman  
DIN : 00061903

Place: Ahmedabad, Gujarat  
Date: July 23, 2024

## ANNEXURE I :

Additional Disclosure as per regulation 52(4) and 54(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015					
Particulars	Regulation No.	Quarter ended			Year ended
		30-Jun-2024	31-Mar-2024	30-Jun-2023	31-Mar-2024
Paid up debt capital		786	786	928	786
Net worth	52(4)(f)	7298	6829	6812	6829
Debenture redemption reserve	52(4)(e)	71	71	107	71
Debt equity ratio (in times)	52(4)(a)	0.40	0.49	0.61	0.49
Debt service coverage ratio (in times)	52(4)(b)	4.85	4.21	0.76	1.72
Interest service coverage ratio (in times)	52(4)(c)	12.55	10.56	7.42	8.80
Current ratio (in times)	52(4)(i)	1.49	1.25	1.24	1.25
Long term debt to working capital (in times)	52(4)(j)	1.09	1.66	1.95	1.66
Bad debts to account receivables ratio (in times)	52(4)(k)	0.00	0.00	0.00	0.00
Current liability ratio (in times)	52(4)(l)	0.52	0.54	0.54	0.54
Total debts to total assets (in times)	52(4)(m)	0.23	0.27	0.32	0.27
Debtors turnover (in times) (Annualised)	52(4)(n)	5.65	5.34	4.81	5.07
Inventory turnover (in times) (Annualised)	52(4)(o)	6.28	5.40	5.28	5.28
Operating margin (in %)	52(4)(p)	37.7%	34.6%	35.2%	34.3%
Net profit margin (in %)	52(4)(q)	19.2%	19.1%	15.2%	15.9%
Assets coverage ratio (in times)	54(3)	3.53	3.46	2.67	3.46

Ratios have been computed as follows :-

- (a) Debt equity ratio : Total debt / Net worth  
 Total debt: Long term borrowings (incl. current maturities) + Short term borrowings  
 Net worth: Equity share capital + Other equity
- (b) Debt service coverage ratio : (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease) / (Interest on debt and lease + Principal repayments of long term debt including lease payment)
- (c) Interest service coverage ratio : (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease) / Interest on debt and lease
- (d) Current ratio : Current assets / Current liabilities
- (e) Long term debt to working capital : Long term debt (incl. current maturities) / Net working capital  
 Net Working capital: Current assets - Current liabilities (excl. current maturities of long term borrowings)
- (f) Bad debts to account receivables ratio : Allowances for expected credit loss / Gross trade receivables
- (g) Current liability ratio : Current liabilities / Total liabilities (excl. total equity)
- (h) Total debts to total assets : Total borrowing / Total assets  
 Total borrowing: long term borrowings (incl. current maturities) + short term borrowings
- (i) Debtors turnover : Net sales / Average trade receivables
- (j) Inventory turnover : Net sales / Average Inventories
- (k) Operating margin % : Revenue from operations - (cost of goods sold + employee benefits + other expenses) + (other income - interest income - Dividend income) / Revenue from operations
- (l) Net profit margin % : Profit after tax / Revenue from operations
- (m) Assets coverage ratio : Total assets available for secured debt securities (secured by either *pari-passu* or exclusive charge on assets including assets given on first *pari-passu* basis to term loan lenders) / Total borrowing through issue of secured Debt securities and other borrowings (secured by first *pari-passu* charge on aforementioned assets) including interest accrued.

